Author details

Full Name

Aguirre A de Cubas

Affiliation

ORCID

Career Start Year

2010

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
36973495	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens.		2023
32493845	DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer.	JCI insight	2020
31410193	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.	Theranostics	2019
29467323	Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch.	JCI insight	2018
30030490	Epigenetic modifiers: activities in renal cell carcinoma.	Nature Reviews Urology	2018
29925010	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.	Cell Rep	2018
30392958	Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.	Cell	2018
30137025	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.	J Clin Invest	2018
30135306	Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.	JCI Insight	2018
29724720	<i>SETD2</i> Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma.	Cancer Res	2018
29617669	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.	Cell Rep	2018
28162975	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.	Cancer Cell	2017
28697319	Renal Medullary Carcinoma: Establishing Standards in Practice.	J Oncol Pract	2017
27695003	Foxp3 and Toll-like receptor signaling balance T<sub>reg</sub> cell anabolic metabolism for suppression.	Nat Immunol	2016
27076078	AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival.	Cell Metab	2016
26652933	Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas.	Journal of Clinical Endocrinology and Metabolism	2016
26070438	Functional and in silico assessment of MAX variants of unknown significance.	J Mol Med (Berl)	2015
25916394	Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations.	European Journal of Endocrinology	2015
25825477	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.	Clin Cancer Res	2015
25766404	Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.	J Natl Cancer Inst	2015
25348618	High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.	Pharmacogenomics J	2015
25720323	MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors.	Mod Pathol	2015
24684458	H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series.	Journal of Clinical Endocrinology and Metabolism	2014
24382797	DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.	International Journal of Cancer	2014
24334767	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.	Human Molecular Genetics	2014
24676840	Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.	Int J Cancer	2014
24754736	VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.	Thyroid	2014
25014000	Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.	J Clin Endocrinol Metab	2014
23660872	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.	Endocr Relat Cancer	2013
24096807	Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.	Endocrine Pathology	2013
23780998	Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.	Endocr Relat Cancer	2013
23404858	Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients.	Endocr Relat Cancer	2013
23201134	Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.	Am J Pathol	2013
23418310	Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.	Hum Mol Genet	2013
22209341	Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results.	Human Pathology	2012
22805305	Hematologic Î²-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity.	Cancer Res	2012
22718863	Regulatory polymorphisms in Î²-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.	Clin Cancer Res	2012
22452945	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.	Clin Cancer Res	2012
21685915	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.	Nat Genet	2011
21538688	Functional analysis of LDLR promoter and 5' UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia.	Human Mutation	2011
20980436	Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.	Mol Endocrinol	2010